close

ViroPharma Incorporated, a biopharmaceutical company, engages in the development and commercialization of products that address serious diseases with a focus on products used by physician specialists or in hospital settings in the United States and internationally. Its products include Vancocin HCl capsules for the treatment of antibiotic-associated pseudomembranous colitis caused by Clostridium difficile infection (CDI) and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains; and Cinryze for the prevention of hereditary angioedema attacks. The company's products in development include Maribavir, which is in Phase III clinical development stage for the prevention and treatment of cytomegalovirus disease; and non-toxigenic strains of C. difficile, which is in preclinical stage for the treatment and prevention of CDI. It licensed the third product development candidate, an intranasal formulation of pleconaril, to Schering-Plough for the treatment of picornavirus infections in the U.S. and Canada. It sells its products directly to wholesale drug distributors, and specialty pharmacies/specialty distributors. The company has strategic relationships with Eli Lilly and Company, GlaxoSmithKline, Schering-Plough Corporation, and Sanofi-Aventis. ViroPharma Incorporated was founded in 1994 and is headquartered in Exton, Pennsylvania.

(login to add this stock to your watchlist or favorites)

Key Statistics

Closing Price	29.79
Volume	(mio) 1.03
Volume Avg	(mio) 1.34
52 Week High	33.17
52 Week Low	14.62
PE	17.74
PE (group average)	39
EPS Year	1.68
EPS change Q/Q	-2.08%
EPS change Q/Q Yr ago	74.07%
EPS change Q/Q next Q est	6.82%
EPS change Y/Y	-50.28%
REV change Q/Q	4.44%
REV change Q/Q Yr ago	40.18%
EPS next Q est	0.44
EPS next Y est	1.89
Divident Annual	0.00
Dividend Yield	0%